A Qualitative Exploration into the Experience of Neuroendocrine Pancreatic Cancer Patients Receiving Molecular Targeted Therapies

被引：0
|
作者：
Quaglia, E. [1 ]
Uzzell, M. [2 ]
Woodcock, J. [2 ]
Caplin, M. [1 ]
机构：
[1] Royal Free London NHS Fdn Trust, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
sunitinib; everolimus;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
L14
引用
收藏
页码：224 / 224
页数：1
相关论文
共 50 条
  • [21] Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies
    Annemilaï Tijeras-Raballand
    Cindy Neuzillet
    Anne Couvelard
    Maria Serova
    Armand de Gramont
    Pascal Hammel
    Eric Raymond
    Sandrine Faivre
    Targeted Oncology, 2012, 7 : 173 - 181
  • [22] Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies
    Tijeras-Raballand, Annemilai
    Neuzillet, Cindy
    Couvelard, Anne
    Serova, Maria
    de Gramont, Armand
    Hammel, Pascal
    Raymond, Eric
    Faivre, Sandrine
    TARGETED ONCOLOGY, 2012, 7 (03) : 173 - 181
  • [23] Advancing targeted therapies in pancreatic cancer: Leveraging molecular abberrations for therapeutic success
    Gupta, Tanvi
    Murtaza, Mohd
    PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2025, 196 : 19 - 32
  • [24] Efficacy of Combined MEK and CDK Targeted Therapies for Pancreatic Neuroendocrine Tumors
    Umesalma, S.
    Kaemmer, C. A.
    Maharjan, C. K.
    Kohlmeyer, J. L.
    Goldfard, D.
    Wilkerson, E.
    Sheehy, R. M.
    Sheehy, M. R.
    Leidinger, M. R.
    Meyerholz, D. K.
    Bell, S.
    Zamba, G.
    O'Dorisio, T. M.
    Dillion, J.
    Scott, A.
    Ear, P. H.
    Braun, T. A.
    Howe, J. R.
    Chandrasekharan, C.
    Bellizzi, A. M.
    Herring, L.
    Graves, L. M.
    Darbro, B. W.
    Quelle, D. E.
    PANCREAS, 2021, 50 (03) : 444 - 444
  • [25] Molecular-targeted therapies for elderly patients with breast cancer
    Awada, A.
    Ismael, G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S5 - S6
  • [26] Targeted therapies in pancreatic cancer: Promises and failures
    Bagherabad, Matineh Barati
    Afzaljavan, Fahimeh
    ShahidSales, Soodabeh
    Hassanian, Seyed Mahdi
    Avan, Amir
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (03) : 2726 - 2741
  • [27] Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
    Aslan, Minela
    Shahbazi, Reza
    Ulubayram, Kezban
    Ozpolat, Bulent
    ANTICANCER RESEARCH, 2018, 38 (12) : 6591 - 6606
  • [28] Combining molecular targeted therapies: clinical experience
    Pivot, Xavier
    Bedairia, Nadia
    Thiery-Vuillemin, Antoine
    Espie, Marc
    Marty, Michel
    ANTI-CANCER DRUGS, 2011, 22 (08) : 701 - 710
  • [29] Molecular Targeted Cancer Therapies and the Kidney
    Aksu, Ozge Bas
    Sadioglu, Rezzan Eren
    Sengul, Sule
    TURKISH JOURNAL OF NEPHROLOGY, 2020, 29 (03): : 232 - 241
  • [30] Cancer Prevention with Molecular Targeted Therapies
    Paleari, Laura
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
12345